NFE2L2 and hepatocellular carcinoma: Thus, reducing NRF2 expression activity in cancer cells can suppress HCC cell growth, reverse the chemotherapeutic resistance of HCC, and enhance the sensitivity of cancer cells to anticancer drugs [10].